pharma · Inflammatory Bowel Disease (IBD) · Melanoma · IRON
Disc Medicine
Disc Medicine is a pharma organization headquartered in Watertown, USA. It trades on NYSE under ticker IRON. Primary therapeutic focus areas include Inflammatory Bowel Disease (IBD), Melanoma, Parkinson's disease, Falcip
Company details
- Status
- Public
- HQ
- 321 Arsenal St., Suite 101, Watertown, Massachusetts 02472-5710, US
- Employees
- 165
- Programs
- 308
- Drugs
- 443
- Patents
- 706
202000570
Phase 2 · small molecule · Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).
202000570 for Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC). is a Phase 2 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Internal code 202000570
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Disc Medicine
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).
- Status
- active
- Trials
- 1